Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice

Vaccine

Volumn 29, Issue 37, 2011, Pages 6236-6241

  Rodriguez, Lissete ^a   Tirado, Yanelys ^a   Reyes, Fatima ^a   Puig, Alina ^a   Kadir, Ramlah ^b   Borrero, Reinier ^a   Fernandez, Sonsire ^a   Reyes, Giselle ^a   Alvarez, Nadine ^a   Garcia, Maria Angeles ^a   Sarmiento, Maria Elena ^a   Norazmi, Mohd Nor ^b   Perez Quinoy, Jose Luis ^a   Acosta, Armando ^a  

^a Instituto Finlay   (Cuba)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

Antibody response; Delayed type hypersensitivity; M. tuberculosis; Mycobacterium smegmatis; Proteoliposomes

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CELL MEMBRANE PROTEIN; FREUND ADJUVANT; IMMUNOGLOBULIN G; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM TUBERCULOSIS ANTIGEN; SOLUBLE CELL WALL PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; CELLULAR IMMUNITY; CROSS REACTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; WHOLE CELL LYSATE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CELL WALL; CROSS REACTIONS; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PROTEOLIPIDS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 80051568423     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.077     Document Type: Article

References (38)

1. Aagaard C., Dietrich J., Doherty M., Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 2009, 87:279-286.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report. WHO Library Cataloguing-in-Publication Data;2008:1-37.
3. Brennan P.J. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis 2003, 83:91-97.
4. Hamasur B., Haile M., Pawlowski A., Schröder U., Williams A., Hatch G., et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 2003, 21:4081-4093.
5. Jeon B.Y., Kim S.C., Jo E.K., Park J.K., Paik T.H., Kim S.J., et al. Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of Triton X-100-soluble cell proteins. J Immunol 2007, 67:18-23.
6. Pérez J.L., Acevedo R., Callicó A., Fernández Y., Cedré B., Año G., et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 2009, 27:205-212.
7. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14:195-207.
8. Sotolongo F., Campa C., Casanueva V., Fajardo E., Cuevas I., González-Gotera N. Cuban Meningococcal BC Vaccine: experiences and contributions from 20 years of application. MEDICC Rev 2007, 9:16-22.
9. Pérez O., Bracho G., Lastre M., Mora N., del Campo J., Gil D., et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 2004, 82:603-610.
10. Langley J.M., Halperin S.A., McNeil S., Smith B., Jones T., Burt D., et al. Safety and immunogenicity of a proteosome™-trivalent inactivated influenza vaccine given nasally to healthy adults. Vaccine 2006, 24:1601-1612.
11. de Diego J.L., Gerold G., Zychlinsky A. Sensing, presenting and regulating PAMPs. Ernst Schering Found Symp Proc 2007, 3:83-95.
12. Tyagi J.S., Sharma D. Mycobacterium smegmatis and tuberculosis. Trends Microbiol 2002, 10:68-69.
13. Bishop P.J., Neumann G. The history of the Ziehl-Neelsen stain. Tubercle 1970, 51:196-206.
14. Rosenkrands I., Agger E., Olsen A., Korsholm K., Swetman C., Jensen K., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 2005, 73:5817-5826.
15. Lowry O.H., Rosbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
16. Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
17. Canadian Council on Animal Care Guide to the care and use of experimental animals 1984, CCAC, Ottawa, Ont, p. 2.
18. Chabot S., Brewer A., Lowell G., Plante M., Cyr S., Burt D.S., et al. A novel intranasal Protollin™-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine 2005, 23:1374-1383.
19. Cyr S.L., Jones T., Stoica-Popescu I., Burt D., Ward B.J. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine. Vaccine 2007, 25:3228-3232.
20. Barry C. Mycobacterium smegmatis: an absurd model for tuberculosis?. Trends Microbiol 2001, 9:473-474.
21. Wang R., Prince J.T., Marcotte E.M. Mass spectrometry of the Mycobacterium smegmatis proteome: protein expression levels correlate with function, operons, and codon bias. Genome Res 2005, 15:1118-1126.
22. Cheadle E.J., O'Donnell D., Selby P.J., Jackson A.M. Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 2005, 73:784-794.
23. Adam A., Ciorbaru R., Petit J.F., Lederer E. Isolation and properties of a macromolecular, water-soluble, immuno-adjuvant fraction from the cell wall of Mycobacterium smegmatis. Proc Natl Acad Sci U S A 1972, 69:851-854.
24. Faisal S.M., Yan W., McDonough S.P., Mohammed H.O., Divers T.J., Chang Y.F. Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis. Vaccine 2009, 27:6129-6136.
25. He Z., De Buck J. Cell wall proteome analysis of Mycobacterium smegmatis strain mc2 155. BMC Microbiol 2010, 10:121.
26. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
27. Mesa C., De Leon J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22:3045-3052.
28. Davenport V., Groves E., Horton R.E., Hobbs C.G., Guthrie T., Findlow J., et al. Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis 2008, 198:731-740.
29. Cohen N.R., Garg S., Brenner M.B. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 2009, 102:1-94.
30. Guiard J., Collmann A., Garcia-Alles L.F., Mourey L., Brando T., Mori L., et al. Fatty acyl structures of Mycobacterium tuberculosis sulfoglycolipid govern T cell response. J Immunol 2009, 182:7030-7037.
31. Nguyen T., Borrero R., Férnandez S., Reyes G., Perez J.L., Reyes R., et al. Evaluation of the potential of Mycobacterium smegmatis as vaccine candidate against tuberculosis by in silico and in vivo studies. VacciMonitor 2010, 19:20-26.
32. Olivares N., León A., López Y., Puig A., Cádiz A., Falero G., et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis 2006, 86:268-272.
33. Olivares N., Puig A., Aguilar D., Moya A., Cadiz A., Otero O., et al. Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis 2009, 89:218-220.
34. López Y., Yero D., Falero-Diaz G., Olivares N., Sarmiento M.E., Sifontes S., et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 2009, 299:447-452.
35. Acosta A., Norazmi M.N., Sarmiento M.E. Antibody mediated immunity-a missed opportunity in the fight against tuberculosis?. Malays J Med Sci 2010, 17:66-67.
36. Kaufmann S.H., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375:2110-2119.
37. Dheda K., Schwander S.K., Zhu B., van Zyl-Smit R.N., Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 2010, 15:433-450.
38. Prados-Rosales R., Baena A., Martinez L.R., Luque-Garcia J., Kalscheuer R., Veeraraghavan U., et al. Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice. J Clin Invest 2011, [PII: 44261]. 10.1172/JCI44261.